Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eloralintide + tirzepatide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
**Eloralintide + tirzepatide** is an investigational combination drug being developed for obesity and weight management, currently in clinical trials. Eloralintide is an amylin analog designed to mimic the metabolic hormone amylin, which controls appetite and gastric emptying; it is being developed as a next-generation therapy for obesity, both as monotherapy and in combination with other agents. Tirzepatide is a dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor, approved for type 2 diabetes, obesity, and weight loss. The combination is under investigation to determine if the addition of eloralintide to tirzepatide can achieve greater, more sustained weight loss compared to single-agent therapy. Both drugs are administered subcutaneously. The developer is Eli Lilly and Company[1][3][5][7].
- Brand names
- Mounjaro
- Other names
- tirzepatide
02
Targets
CALCR (Calcitonin receptor)GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)AMY3 (Amylin receptor 3)AMY (Pancreatic alpha-amylase)
Beyond the preview
Go deeper on eloralintide + tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eloralintide + tirzepatide.